Absolute Contraindications and Allergy Risks for Tepotinib

Release date: 2026-06-17 16:28:16     Recommended: 12

Absolute Contraindications and Allergy Risks for Tepotinib

Tepotinib is strictly contraindicated in patients with known hypersensitivity to tepotinib or to any of its excipients. If you have experienced allergic reactions to similar drugs in the past, you must proactively inform your physician. Allergic symptoms may include rash, pruritus, swelling of the face or throat, dyspnea, etc. In addition, pregnant women should generally not take this medicinal product unless explicitly directed by a physician after thorough risk-benefit assessment. A pregnancy test is recommended prior to treatment to ensure safety.

Warnings for Vital Organ Function Monitoring

Tepotinib may cause sudden onset of dyspnea, cough, or fever, which could be signs of severe interstitial lung disease requiring immediate medical attention. Your physician will closely monitor pulmonary symptoms during treatment, interrupt dosing if necessary, and administer appropriate management. Meanwhile, liver function parameters (transaminases, alkaline phosphatase, etc.) and renal function parameters (creatinine) may become elevated, so regular blood tests before and during therapy are required. For cardiac effects, this medicinal product may affect the ECG QT interval; therefore, electrocardiograms will be arranged as clinically indicated, especially for patients with pre-existing cardiac conditions or those taking other drugs that affect cardiac rhythm.

Contraception Requirements and Drug Interactions

Both males and females must use effective contraception during treatment and for at least 1 week after the last dose. Women of childbearing potential should use reliable contraceptive methods; if hormonal contraceptives (e.g., oral contraceptives) are used, an additional barrier method must be added because this medicinal product may reduce hormonal efficacy. Male patients should also use barrier contraception to avoid partner pregnancy. Breastfeeding should be discontinued during treatment and for 1 week after the last dose. Furthermore, this medicinal product has multiple drug interactions, including with dabigatran, digoxin, aliskiren, everolimus, sirolimus, rosuvastatin, methotrexate, topotecan, and metformin, which may affect their plasma concentrations or increase the risk of adverse reactions. You must inform your physician of all medications you are currently taking.